GlyProVac
GlyProVac is developing a glycoprotein-based vaccine targeting Enterotoxigenic Escherichia coli (ETEC), a leading cause of bacterial diarrhea in travelers and children in developing countries. This vaccine aims to provide effective immunity against ETEC, reducing the incidence of gastrointestinal infections and associated healthcare costs.
- Biotechnology
Updated 23 months ago
Funding
Raised to date
$467KRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Features
- GlyProVac is developing a glycoprotein-based vaccine targeting Enterotoxigenic Escherichia coli (ETEC), a leading cause of bacterial diarrhea in travelers and children in developing countries. This vaccine aims to provide effective immunity against ETEC, reducing the incidence of gastrointestinal infections and associated healthcare costs.